Catapult invests in Biohabit through the GM&C Life Sciences Fund
Catapult has completed a seed investment into Alderley Park based Biohabit through the Greater Manchester and Cheshire Life Sciences Fund.
Biohabit are developing a salivary test for the diagnosis of heart failure, which hopes to replace the need for existing blood tests. By developing a test that is readily available in multiple healthcare settings, the company are aiming to reduce the time to diagnosis and reducing the costs involved for healthcare services. This has the added benefit of being able to better triage care for patients at the earliest available opportunity and better monitor disease progression.
Cardiovascular diseases are on the rise and heart failure is an ever-increasing problem in our ageing population; by reducing the barriers to disease diagnosis, Biohabit will be able to both serve this market, and open up new avenues for self-care and closer patient management.
This funding will enable them to run a a trial and continue to develop their product
